Laizhou City Peoples Hospital

Weichanglu, China

Laizhou City Peoples Hospital

Weichanglu, China
SEARCH FILTERS
Time filter
Source Type

Luan Z.M.,Affiliated Hospital of WeiFang Medical College | Zhang H.,Affiliated Hospital of WeiFang Medical College | Qu X.L.,LaiZhou City Peoples Hospital
Genetics and Molecular Research | Year: 2016

This study determined the level of PITX2 methylation in prostate cancer and benign tissues and its relationship with the postoperative survival rate. Forty-four patients with prostate cancer who underwent radical prostatectomy and 43 patients with benign prostatic hyperplasia were selected. DNA was extracted from the tissues and PITX2 methylation status was quantitatively analyzed by using the EpiTect MethyLight method. The median follow-up time of the patients was 63 months and was used to analyze the relationship between PITX2 methylation status with tumor stage and survival rates. Median PITX2 gene expression in benign tissues was 1.46, which was higher than that of tumor tissues with a median of 0.01 (P < 0.001). The median methylation in the controls was less than 0.001%, while the median methylation in the test group was 23.3% (P = 0.000). The number of patients with low methylation level in T2 stage was 15, which was more than that in T3 and T4 stages (8 patients); while the number of patients with high methylation levels in T2 stage was 6, which was less than that in T3 and T4 stages (15 patients) (P = 0.035). The PITX2 gene expression level in prostate cancer tissues was lower than that in benign tissues. A higher degree of PITX2 DNA methylation was associated with higher tumor stage and lower survival rates. PITX2 DNA methylation presents a good predictive value for prostate cancer survival. © FUNPEC-RP.


Sha H.,Qingdao University | Guo S.,Laizhou City Peoples Hospital | Liu Y.,Bohai Pharmaceutical Group Co. | Zhao J.,Qingdao University
International Journal of Clinical and Experimental Medicine | Year: 2016

Objective: To explore the clinical efficacy and safety of acitretin plus Qinzhu Liangxue Decoction in the treatment of psoriasis vulgaris. Method: A total of 72 eligible patients with psoriasis vulgaris were enrolled and randomized to into the acitretin group and the acitretin plus Qinzhu Liangxue Decoction group. The clinical efficacy and laboratory tests were measured at baseline and at 4 or 8 weeks. Results: Both initial PASI (psoriasis area and severity index) and DLQI (Dermatology Life Quality Index) were significantly decreased in two groups at 4 and 8 weeks. There was a better improvement of PASI or DLQI in the experimental group than those in the control group at 8 weeks. However, there was no significant difference in the DLQI improvement between two groups at 4 weeks. Compared with the control group, the treatment success rates in the experimental group was significant higher after 8 week of treatment. The serum levels of tumor necrosis factor-α (TNF-α), interleukin-8 (IL-8), IL-22, macrophage inflammatory protein-1α (MIP-1α), MIP-1β and monocyte chemoattractant protein-1 (MCP-1) were dramatically declined both two groups at week 4 and week 8. The TNF-α, IL-8, IL-22, MIP-α, MIP-β and MCP-1 levels in the experimental group were significantly lower than those of control group 4 weeks or 8 weeks after treatment. Conclusion: Combination of acitretin with Qinzhu Liangxue Decoction have an exactly therapeutical efficacy in the psoriasis vulgaris associated with the negative regulation of TNF-α, IL-8, IL-22, MIP-1α, MIP-1β and MCP-1. © 2016, E-Century Publishing Corporation. All rights reserved.


PubMed | Affiliated Hospital of WeiFang Medical College and LaiZhou City Peoples Hospital
Type: Journal Article | Journal: Genetics and molecular research : GMR | Year: 2016

This study determined the level of PITX2 methylation in prostate cancer and benign tissues and its relationship with the postoperative survival rate. Forty-four patients with prostate cancer who underwent radical prostatectomy and 43 patients with benign prostatic hyperplasia were selected. DNA was extracted from the tissues and PITX2 methylation status was quantitatively analyzed by using the EpiTect MethyLight method. The median follow-up time of the patients was 63 months and was used to analyze the relationship between PITX2 methylation status with tumor stage and survival rates. Median PITX2 gene expression in benign tissues was 1.46, which was higher than that of tumor tissues with a median of 0.01 (P < 0.001). The median methylation in the controls was less than 0.001%, while the median methylation in the test group was 23.3% (P = 0.000). The number of patients with low methylation level in T2 stage was 15, which was more than that in T3 and T4 stages (8 patients); while the number of patients with high methylation levels in T2 stage was 6, which was less than that in T3 and T4 stages (15 patients) (P = 0.035). The PITX2 gene expression level in prostate cancer tissues was lower than that in benign tissues. A higher degree of PITX2 DNA methylation was associated with higher tumor stage and lower survival rates. PITX2 DNA methylation presents a good predictive value for prostate cancer survival.

Loading Laizhou City Peoples Hospital collaborators
Loading Laizhou City Peoples Hospital collaborators